Search

Displaying results 7801 - 7810 of 10000 in total
  1. Drug

    Surufatinib

    go.drugbank.com/drugs/DB15106
    Investigational

    Surufatinib is under investigation in clinical trial NCT02588170 (Phase III Study of Surufatinib in Treating Advanced Extrapancreatic Neuroendocrine Tumors).

  2. Drug

    Olorofim

    go.drugbank.com/drugs/DB15245
    Investigational

    Olorofim is under investigation in clinical trial NCT03340597 (Assessment of Varying Oral Dosing Regimens for F901318 in Healthy Subjects).

  3. Drug

    Aganirsen

    go.drugbank.com/drugs/DB15369
    Investigational

    Aganirsen is under investigation in clinical trial NCT02947867 (Trial of Aganirsen in iCRVO Patients at Risk of Developing NVG).

  4. Drug

    Balixafortide

    go.drugbank.com/drugs/DB15370
    Investigational

    Balixafortide is under investigation in clinical trial NCT03786094 (Pivotal Study in HER2 Negative, Locally Recurrent or Metastatic Breast Cancer).

  5. Drug

    Ladiratuzumab vedotin

    go.drugbank.com/drugs/DB15409
    Investigational

    Ladiratuzumab vedotin is under investigation in clinical trial NCT01969643 (A Safety Study of SGN-LIV1A in Breast Cancer Patients).

  6. Drug

    Volenrelaxin

    go.drugbank.com/drugs/DB21750
    Investigational

    Volenrelaxin is under investigation in clinical trial NCT06598631 (Efficacy and Safety of Volenrelaxin in Adults With Chronic Kidney Disease).

  7. Drug

    Eptifibatide

    go.drugbank.com/drugs/DB00063
    ApprovedInvestigational

    Derived from venom of the Southeastern pygmy rattlesnake (Sistrurus miliarus barbouri), eptifibatide is a cyclic heptapeptide that belongs to the class of arginin-glycin-aspartat-mimetics.

  8. Drug

    Nomacopan

    go.drugbank.com/drugs/DB14991
    Investigational

    Nomacopan is under investigation in clinical trial NCT03427060 (Coversin in PNH in Patients With Resistance to Eculizumab Due to Complement C5 Polymorphisms).

  9. Drug

    Isuzinaxib

    go.drugbank.com/drugs/DB19109
    Investigational

    Isuzinaxib is under investigation in clinical trial NCT05758896 (Study of APX-115 in Contrast Induced Acute Kidney Injury in Subjects Undergoing PCI).

  10. Drug

    Streptococcus pneumoniae type 10A capsular polysaccharide diphtheria CRM197 protein conjugate antigen

    go.drugbank.com/drugs/DB16714
    ApprovedInvestigational

    The saccharides in the vaccine are prepared from purified polysaccharides that are chemically activated then conjugated to the protein carrier CRM197 to form the glycoconjugate. … * serotype 10A individually conjugated to the CRM197 protein, a nontoxic variant of diphtheria toxin isolated from cultures of *Corynebacterium diphtheriae* strain C7 (β197).